OS data were still immature at the time of the first analysis presented but, given the striking surrogate results of PFS and CNS disease control, this approach is expected to become the new standard of care in the near future for patients with unresectable locally advanced EGFR-positive NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.